Decoy Therapeutics (NASDAQ:DCOY) Releases Quarterly Earnings Results

Decoy Therapeutics (NASDAQ:DCOY) announced its earnings results on Wednesday. The company reported ($4.46) EPS for the quarter, FiscalAI reports. The firm had revenue of $0.23 million during the quarter.

Decoy Therapeutics Price Performance

Shares of DCOY stock traded up $0.10 during trading hours on Friday, reaching $3.63. 7,981 shares of the company were exchanged, compared to its average volume of 180,399. Decoy Therapeutics has a fifty-two week low of $3.50 and a fifty-two week high of $85.20. The stock’s fifty day moving average is $5.54 and its two-hundred day moving average is $6.63. The company has a market cap of $2.14 million, a price-to-earnings ratio of -0.03 and a beta of 0.64.

Analyst Ratings Changes

Separately, Weiss Ratings raised Decoy Therapeutics from a “sell (e)” rating to a “sell (e+)” rating in a research note on Friday, June 12th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Decoy Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $30.00.

Decoy Therapeutics Company Profile

Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577.